Ubrelvy (ubrogepant) is a medication used for the acute treatment of migraine with or without aura in adults. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
How does Ubrelvy work for migraines?
Ubrelvy functions by blocking the action of CGRP, a molecule that plays a role in migraine pain. By inhibiting CGRP, Ubrelvy is thought to reduce neuroinflammation and vasodilation associated with migraines [1].
When can I take Ubrelvy?
Ubrelvy is prescribed for the acute treatment of an ongoing migraine attack. It should not be used to prevent migraines [1].
What are the potential side effects of Ubrelvy?
Common side effects of Ubrelvy include nausea, tiredness, and dry mouth [1].
Can Ubrelvy be taken with other migraine medications?
Ubrelvy should not be taken with other CGRP receptor antagonists [1]. Information regarding interactions with other acute migraine treatments is available [2].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [1].
What is the patent status for Ubrelvy?
Information regarding patents for Ubrelvy can be found on DrugPatentWatch.com [3]. Drug patents determine how long a drug manufacturer has exclusive rights to sell a medication. Challenges to these patents can lead to earlier market entry for generic versions.
What are the alternatives to Ubrelvy for migraine treatment?
Other classes of medications used for acute migraine treatment include triptans and NSAIDs. Preventative migraine treatments are also available for individuals experiencing frequent or disabling migraines [4].